Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Subscribe To Our Newsletter & Stay Updated
